NUWE NUWELLIS INC

Nuwellis, Inc. To Report First Quarter 2025 Financial Results on May 13, 2025

Nuwellis, Inc. To Report First Quarter 2025 Financial Results on May 13, 2025

MINNEAPOLIS, April 22, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage medical technology company focused on transforming the lives of people with fluid overload, today announced that it will release financial results for the first quarter 2025 on May 13, 2025. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update.

To access the live webcast, please visit the Investors page of the Nuwellis website at . Alternatively, you may access the live conference call by dialing 1-800-579-2543 (U.S) or 1-785-424-1789 (international) and using the conference ID: NUWEQ1. An audio archive of the webcast will be available following the call on the Investors page at .

About Nuwellis

Nuwellis, Inc. (Nasdaq: NUWE) is a commercial-stage medical technology company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, with a wholly owned subsidiary in Ireland. For more information visit or visit us on or .

About the Aquadex SmartFlow® System 

The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.

CONTACTS

INVESTORS:

Louisa Smith

Gilmartin Group LLC



EN
22/04/2025

Underlying

NUWENUWELLIS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NUWELLIS INC

 PRESS RELEASE
Free
NUWE NUWELLIS INC

Nuwellis Expands IP Portfolio with Patent That Reduces Clinical Burden...

Nuwellis Expands IP Portfolio with Patent That Reduces Clinical Burden, Preserves Precision WHOWHATWHEREWHENWHYNuwellis, Inc.Issuance of U.S. Patent No. 12,280,007.United States Patent and Trademark OfficeApril 22, 2025To protect a novel self-emptying fluid bag design that improves nursing workflow while maintaining system accuracy. MINNEAPOLIS, April 24, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on fluid management solutions for patients with fluid overload, today announced the issuance of U.S. Patent No. 12,280,007 by the U.S. Patent an...

11h / 24m 1 EN
 PRESS RELEASE
Free
NUWE NUWELLIS INC

Nuwellis, Inc. To Report First Quarter 2025 Financial Results on May 1...

Nuwellis, Inc. To Report First Quarter 2025 Financial Results on May 13, 2025 MINNEAPOLIS, April 22, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage medical technology company focused on transforming the lives of people with fluid overload, today announced that it will release financial results for the first quarter 2025 on May 13, 2025. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update. To access the live webcast, please visit the Investors page of the Nuwellis website at . Alt...

April 22, 2025 1 EN
 PRESS RELEASE
Free
NUWE NUWELLIS INC

Nuwellis, Inc. Announces Fourth Quarter and Full Year 2024 Financial R...

Nuwellis, Inc. Announces Fourth Quarter and Full Year 2024 Financial Results MINNEAPOLIS, March 11, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage medical device company focused on transforming the lives of people with fluid overload, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights: CMS four-fold payment increase to $1,639 for Aquadex Ultrafiltration Therapy in the outpatient setting effective January 1, 2025.New data published in JACC: Hea...

March 11, 2025 1 EN
 PRESS RELEASE
Free
NUWE NUWELLIS INC

Nuwellis Announces Retirement of Nestor Jaramillo, Jr. as President an...

Nuwellis Announces Retirement of Nestor Jaramillo, Jr. as President and CEO John Erb, Current Chair of the Board, Appointed Interim President and CEO MINNEAPOLIS, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, announced today that Nestor Jaramillo, Jr. retired as President and Chief Executive Officer and as a director of the company, effective February 18, 2025. John Erb, who currently serves as Chairman of the company's Board of Directors, assumed the role of Interim Presiden...

February 24, 2025 1 EN
 PRESS RELEASE
Free
NUWE NUWELLIS INC

JACC: Heart Failure Paper Reports Promising Findings of Aquadex Therap...

JACC: Heart Failure Paper Reports Promising Findings of Aquadex Therapy in Updated AVOID-HF Study Analysis WHOWHATWHEREWHENWHYNuwellis, Inc., and Dr. Sean P. Pinney and Dr. Maria V. DeVitaUpdated analysis of the AVOID-HF study data shows that Aquadex® SmartFlow ultrafiltration therapy led to a 60% reduction in heart failure events compared to standard diuretic therapy.Findings were recently updated and analyzed as of 2/19/25These promising results support further research into ultrafiltration's role in heart failure management and highlight its potential to improve treatment outcomes, suppo...

February 20, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch